Literature DB >> 15555841

Posterior heel pain (retrocalcaneal bursitis, insertional and noninsertional Achilles tendinopathy).

Michael S Aronow1.   

Abstract

The majority of patients with Achilles tendinopathy respond to nonoperative treatment. In patients with refractory symptoms, surgery can be considered. If paratenonitis is present, the paratenon is partially excised, and adhesions are released. Areas of symptomatic tendinosis are excised with repair of the residual defect in the Achilles tendon. An alternative for patients with tendinosis who are at increased risk for wound problems or who do not want a large open incision is percutaneous or endoscopic tenotomy. A symptomatic Haglund's deformity or inflamed retrocalcaneal bursa is excised. Augmentation of the Achilles tendon may be considered if debridement threatens the structural integrity of the tendon, in older patients, and in revision surgery.

Entities:  

Mesh:

Year:  2005        PMID: 15555841     DOI: 10.1016/j.cpm.2004.08.003

Source DB:  PubMed          Journal:  Clin Podiatr Med Surg        ISSN: 0891-8422            Impact factor:   1.231


  4 in total

1.  Acetic acid iontophoresis for the treatment of insertional Achilles tendonitis.

Authors:  Roger Lee Kilfoil; Garry Shtofmakher; Gregory Taylor; Jessica Botvinick
Journal:  BMJ Case Rep       Date:  2014-07-23

Review 2.  Treatment for insertional Achilles tendinopathy: a systematic review.

Authors:  J I Wiegerinck; G M Kerkhoffs; M N van Sterkenburg; I N Sierevelt; C N van Dijk
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-10-06       Impact factor: 4.342

3.  The clinical diagnosis of Achilles tendinopathy: a scoping review.

Authors:  Wesley Matthews; Richard Ellis; James Furness; Wayne A Hing
Journal:  PeerJ       Date:  2021-09-28       Impact factor: 2.984

4.  The Achilles tendon and the retrocalcaneal bursa: An anatomical and radiological study.

Authors:  P A Pękala; B M Henry; J R Pękala; K Piska; K A Tomaszewski
Journal:  Bone Joint Res       Date:  2017-07       Impact factor: 4.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.